Pompe Disease Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, Pompe Disease pipeline constitutes 15+ key companies continuously working towards developing 20+ Pompe Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Pompe Disease Overview
Pompe disease belongs to the 'lysosomal storage disorders' (LSDs) group of diseases. Within the cells, lysosomes are tiny compartments where all sorts of substances are recycled. By the action of digestive enzymes, the compounds are degraded. There are currently more than 50 different LSDs that are considered to be caused by the deficiency of one of these enzymes.

"Pompe Disease Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Pompe Disease Market.

The Pompe Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Pompe Disease Pipeline Report: https://www.delveinsight.com/report-store/pompe-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Pompe Disease treatment therapies with a considerable amount of success over the years. Pompe Disease Key players such as - M6P Therapeutics, Entrada Therapeutics, Maze Therapeutics, Astellas Gene Therapies, Asklepios Biopharmaceutical, Spark Therapeutics, Amicus Therapeutics, and others, are developing therapies for the Pompe Disease treatment
• Pompe Disease Emerging therapies such as - M 021, GYS1 Knockdown Oligonucleotide, MZE 001, AT845, AAV2/8LSPhGAA, SPK-3006, Cipaglucosidase alfa, and others are expected to have a significant impact on the Pompe Disease market in the coming years.
• In February 2020, Amicus Therapeutics initiated an open-label study of the safety, pharmacokinetics, efficacy, pharmacodynamics, and immunogenicity of ATB200/AT2221 in pediatric subjects aged0 to < 18 years with Pompe Disease.
• In May 2022, Amicus Therapeutics announced that the U.S. FDA had extended the review period by 90 days forthe Biologics License Application (BLA) for cipaglucosidase alfa and the New Drug Application (NDA) for miglustat,the two components of AT-GAA
• In December 2021, Amicus Therapeutics (announced that the European Medicines Agency (EMA) validated the Marketing Authorization Applications (MAA) for AT-GAA, the Company's investigational two-component therapy for the treatment of Pompe disease.

Route of Administration
Pompe Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Molecule Type
Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Pompe Disease Pipeline Therapeutics Assessment
• Pompe Disease Assessment by Product Type
• Pompe Disease By Stage and Product Type
• Pompe Disease Assessment by Route of Administration
• Pompe Disease By Stage and Route of Administration
• Pompe Disease Assessment by Molecule Type
• Pompe Disease by Stage and Molecule Type

DelveInsight's Pompe Disease Report covers around 20+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Some of the key companies in the Pompe Disease Therapeutics Market include:
Key companies developing therapies for Pompe Disease are - Spark Therapeutics, Amicus Therapeutics, Asklepios Biopharmaceutical, Audentes Therapeutics, Rocket Pharmaceuticals, Avidity Biosciences, AVROBIO, Maze Therapeutics, Denali Therapeutics, and others.

Emerging Pompe Disease Drugs Under Different Phases of Clinical Development Include:
• M 021: M6P Therapeutics
• GYS1 Knockdown Oligonucleotide: Entrada Therapeutics
• MZE 001: Maze Therapeutics
• AT845: Astellas Gene Therapies
• AAV2/8LSPhGAA: Asklepios Biopharmaceutical
• SPK-3006: Spark Therapeutics
• Cipaglucosidase alfa: Amicus Therapeutics

Get a Free Sample PDF Report to know more about Pompe Disease Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/pompe-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Pompe Disease Pipeline Analysis:
The Pompe Disease pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Pompe Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pompe Disease Treatment.
• Pompe Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Pompe Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pompe Disease market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Pompe Disease product details are provided in the report. Download the Pompe Disease pipeline report to learn more about the emerging Pompe Disease therapies at:
https://www.delveinsight.com/sample-request/pompe-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Pompe Disease Pipeline Market Drivers
• Improving Healthcare Infrastructure
• Demand for New and Effective Drugs
• Increasing research and development in the gene therapy and enzyme replacement therapy areas

Pompe Disease Pipeline Market Barriers
• Lack Of Cost-Effective Treatment

Scope of Pompe Disease Pipeline Drug Insight
• Coverage: Global
• Key Pompe Disease Companies: M6P Therapeutics, Entrada Therapeutics, Maze Therapeutics, Astellas Gene Therapies, Asklepios Biopharmaceutical, Spark Therapeutics, Amicus Therapeutics, and others
• Key Pompe Disease Therapies: M 021, GYS1 Knockdown Oligonucleotide, MZE 001, AT845, AAV2/8LSPhGAA, SPK-3006, Cipaglucosidase alfa, and others
• Pompe Disease Therapeutic Assessment: Pompe Disease current marketed and Pompe Disease emerging therapies
• Pompe Disease Market Dynamics: Pompe Disease market drivers and Pompe Disease market barriers

Request for Sample PDF Report for Pompe Disease Pipeline Assessment and clinical trials- https://www.delveinsight.com/sample-request/pompe-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1 Pompe Disease Report Introduction
2 Pompe Disease Executive Summary
3 Pompe Disease Overview
4 Pompe Disease- Analytical Perspective In-depth Commercial Assessment
5 Pompe Disease Pipeline Therapeutics
6 Pompe Disease Late Stage Products (Phase II/III)
7 Pompe Disease Mid Stage Products (Phase II)
8 Pompe Disease Early Stage Products (Phase I)
9 Pompe Disease Preclinical Stage Products
10 Pompe Disease Therapeutics Assessment
11 Pompe Disease Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Pompe Disease Key Companies
14 Pompe Disease Key Products
15 Pompe Disease Unmet Needs
16 Pompe Disease Market Drivers and Barriers
17 Pompe Disease Future Perspectives and Conclusion
18 Pompe Disease Analyst Views
19 Appendix
20 About DelveInsight
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report to know more about Pompe Disease drugs and therapies- https://www.delveinsight.com/sample-request/pompe-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Related Reports:

Pompe Disease Market https://www.delveinsight.com/report-store/pompe-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Pompe Disease-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Pompe Disease Epidemiology https://www.delveinsight.com/report-store/pompe-disease-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Pompe Disease Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Related Reports By DelveInsight -

Hypertrophic Scar Market
https://www.delveinsight.com/report-store/hypertrophic-scar-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Hypertrophic Scar Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Hypertrophic Scar, historical and forecasted epidemiology as well as the Hypertrophic Scar market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Lung Fibrosis Market https://www.delveinsight.com/report-store/lung-fibrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Lung Fibrosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Lung Fibrosis, historical and forecasted epidemiology as well as the Lung Fibrosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Anterior Uveitis Market https://www.delveinsight.com/report-store/anterior-uveitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Anterior Uveitis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Anterior Uveitis, historical and forecasted epidemiology as well as the Anterior Uveitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

22q11.2 deletion syndrome Market https://www.delveinsight.com/report-store/22q112-deletion-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "22q11.2 Deletion Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the 22q11.2 Deletion Syndrome, historical and forecasted epidemiology as well as the 22q11.2 Deletion Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

X-Linked Retinitis Pigmentosa (XLRP) Market https://www.delveinsight.com/report-store/x-linked-retinitis-pigmentosa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "X-Linked Retinitis Pigmentosa Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the X-Linked Retinitis Pigmentosa (XLRP), historical and forecasted epidemiology as well as the X-Linked Retinitis Pigmentosa market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Recent Blog's By DelveInsight:

• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry
https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Contact Us:

Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
www.delveinsight.com/consulting

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.